New drug cocktail shows promise for shrinking lung tumors before surgery

NCT ID NCT07354061

Recruiting now Disease control Sponsor: Tang-Du Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether giving ensartinib plus chemotherapy before surgery can shrink tumors in people with ALK-positive non-small cell lung cancer. About 20 participants with stage II to IIIB cancer will receive the drug combo for 9 weeks, then have surgery. Researchers will check how many tumors completely disappear and monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ensartinib combined with pemetrexed and carboplatin
What this could lead to: If successful, this could lead to a new treatment option that shrinks ALK-positive lung tumors before surgery, potentially improving surgical outcomes and long-term survival.
What could go wrong: This is an early-phase trial with only 20 participants and no comparison group. The combination may cause side effects, and it's unknown if it will work better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (NON-SMALL CELL LUNG CANCER)

Contacts and locations

Locations

Tangdu Hospital
RECRUITING

Xi’an, Shanxi, 710038, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.